Business Wire - September 26, 2002
Six of these posters will showcase the Company's new lead antibacterial molecule DRF 8417.
The ICAAC annual conference is the world's premier meeting on infectious diseases and antimicrobial agents and is organized by the American Society for Microbiology. Over 12,000 scientists from around the world participate in ICAAC to exchange information and foster global solutions to the challenges of HIV/AIDS, anthrax, smallpox, and other topics including bio-terrorism preparedness, recognition, detections, and medical treatments.
DRF 8417, currently in preclinical development, is a novel antibacterial molecule belonging to the chemical class of oxazolidinones. In preclinical studies, the molecule's in vitro and in vivo activity was observed to be several folds better than linezolid. (Linezolid, an oxazolidinone launched in the year 2000, is the first from a completely new class of antibiotics to reach the market in over three decades.) DRF 8417 was derived from systematic Structure Activity Relationship (SAR) studies.
Further, DRF 8417 shows good activity against both Gram-positive and Gram-negative bacteria that cause Community Acquired Pneumonia (CAP). The clinical management of bacteria causing CAP has, in recent times, become more challenging due to drug resistance.
Dr. Reddy's cutting-edge drug discovery effort is orchestrated through its state-of-the-art research facilities in Atlanta and Hyderabad. The Atlanta team uses genomics-based approaches for discovering new targets and NCEs in the areas of atherosclerosis, restenosis, diabetic nephropathy and arthritis. The drug discovery program at Hyderabad focuses on metabolic disorders with an emphasis on type 2 diabetes, dyslipidemia & obesity, cancer, inflammation and bacterial infections. The research pipeline of Dr. Reddy's currently has 3 molecules in clinical development and 7 molecules in preclinical development.
About Dr. Reddy's
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven basic research capabilities. The company develops, manufactures and markets a wide range of pharmaceutical products in India and overseas. Dr. Reddy's produces finished dosage forms, active pharmaceutical ingredients, diagnostic kits, critical care and biotechnology products. The basic research programme of Dr. Reddy's focuses on cancer, diabetes, bacterial infections and pain management.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
CONTACT: Dr. Reddy's US & Europe: Artie Rokkam, 201/760-2880 artie@drreddys.com or Asia Pacific: Nikhil Shah, +91-40-6511532 nikhilshah@drreddys.com
SOURCE: Dr. Reddy's Laboratories Ltd.
020926
BW020906
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .